PRDM16-DT:与阿尔茨海默病相关的大脑和天体细胞特异性 lncRNA
Sophie Schröder1, Ulrike Fuchs1, Verena Gisa1
1Department for Systems Medicine and Epigenetics, German Center for Neurodegenerative Diseases (DZNE), Göttingen, Germany.
bioRxiv : the preprint server for biology
|July 15, 2024
概括
长长的非编码RNAPRDM16-DT对于天体细胞功能和神经元支持至关重要. 它在阿尔茨海默病中的降低调节表明PRDM16-DT是神经退行症的潜在治疗点.
科学领域:
- 神经科学是一个神经科学.
- 分子生物学分子生物学
- 遗传学 遗传学 是一个
背景情况:
- 星球细胞对神经元健康至关重要,但它们的功能障碍导致神经退行性疾病,如阿尔茨海默氏症 (AD).
- 长非编码RNAs (lncRNAs) 正在成为细胞过程中的关键调节者,但它们在天体细胞功能和AD中的作用仍未得到充分研究.
- 准星球细胞功能提供了一个有前途的战略,用于早期干预AD的发病.
研究的目的:
- 识别和描述与阿尔茨海默病相关的新型调节分子,特别是参与天体细胞功能的lncRNAs.
- 研究lncRNAPRDM16-DT在维持星细胞平衡和支持神经元功能的作用.
- 在AD的背景下探索PRDM16-DT的治疗潜力.
主要方法:
- 生物信息分析以识别大脑丰富的lncRNAs,专注于天体细胞特异性表达.
- 在星球细胞中对PRDM16-DT及其小鼠同类Prdm16os进行了淘汰实验.
- 评估星球细胞功能,包括谷氨酸的摄取,乳酸释放和神经元脊柱密度.
- 涉及Rest和PRC的分子相互作用的研究2.2.
- 在AD模型中进行过度表达研究的CRISPR介导基因编辑.
主要成果:
- 鉴定出 lncRNA PRDM16-DT 在人类天体细胞中具有高度丰富性,并在AD大脑和模型中降低调节.
- 击败PRDM16-DT/Prdm16os损害了天体细胞平衡和神经元支持功能.
- PRDM16-DT/Prdm16os通过休息和PRC2调节参与谷氨酸摄取,乳酸释放和神经元脊柱密度的基因.
- 使用CRISPR过度表达Prdm16os,部分挽救了AD相关刺激引起的天体细胞缺陷.
结论:
- PRDM16-DT是天体细胞功能和神经元支持的关键调节者,对于保持大脑健康至关重要.
- 降低PRDM16-DT的调节与阿尔茨海默病的病原发生有关.
- PRDM16-DT是神经退行性疾病的新且有前途的治疗标,其特征是天体细胞功能障碍.
相关概念视频
lncRNA - Long Non-coding RNAs
8.5K
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
8.5K
Alzheimer's Disease: Overview
461
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
461


